Literature DB >> 10498216

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

O Lavergne1, J Harnett, A Rolland, C Lanco, L Lesueur-Ginot, D Demarquay, M Huchet, H Coulomb, D C Bigg.   

Abstract

BN 80927, a novel homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation and shows pronounced cytotoxicity against HT29, SKOV-3, DU145 and MCF7 human tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498216     DOI: 10.1016/s0960-894x(99)00428-x

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

Review 2.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.